Metabolomics Market Outlook:
Metabolomics Market size was over USD 4.2 billion in 2025 and is estimated to reach USD 15.04 billion by the end of 2035, exhibiting a CAGR of 13.8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of metabolomics is assessed at USD 4.7 billion.
The increasing incidence of chronic metabolic diseases is fostering a notable surge in targeted diagnostics and drug development, thereby fueling the market. The market is further driven by the behavioral risk factors such as harmful use of tobacco, physical inactivity, alcohol, and an unhealthy diet. As per the NLM article released in March 2024 states that the metabolic syndrome prevalence among men and women is 22% and 24%. These demographics highlight an expanding consumer base, resulting in a continuous rise in demand in this sector.
According to the Pfizer report in 2025, the overview of metabolic disorders depicts that the prevalence is mostly found in diabetic patients. Further, in the U.S. population, nearly 37.3 million people are suffering from metabolic disorders, which is 11.3% of the overall population. This metabolic syndrome increases the risk of cardiovascular diseases and stroke in patients also it is estimated that 1 in 3 adults has metabolic syndrome. Moreover, the rising patient pool indicates the need for innovation in drugs and robust R&D to address the errors in the metabolic process.
